Leiden, The Netherlands, January 3, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square.

Ronald Loggers, CEO of ISA Pharmaceuticals, will present at Biotech Showcase™ as follows:

Date: Tuesday, January 9, 2018

Time: 9:45am (PST)

Room: Hilton / Franciscan C, Ballroom Level

Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

###

About ISA Pharmaceuticals

ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP^®) concept and AMPLIVANT^® technology. SLP^® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP^® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops MyISA^®, a personalized SLP^® immunotherapy, targeting tumor-specific, mutation-derived neo-antigens.

For more information, please visit www.isa-pharma.com.

SLP^®, AMPLIVANT^® and MyISA^® are registered trademarks in Europe.

Contact & Media Inquiries:
akampion
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, Tel. +49 30 23 63 27 68
info(at)akampion.com